Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026)
Lexeo Therapeutics recorded quarterly Return on Capital Employed of 39.86% in Q1 2026, up 30.88% quarter-over-quarter from 57.67% in Q4 2025, and down 1030.0% year-over-year from 4.29% in Q1 2025.
Lexeo Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 39.86% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1030.0% year-over-year to 39.86%; the TTM figure through Mar 2026 stood at 39.86% (down 1030.0% YoY), while the FY2025 annual figure was 57.2%, down 4005.0% from the prior year.
- Return on Capital Employed came in at 39.86% for Q1 2026 at Lexeo Therapeutics, up from 57.67% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 15.03% in Q4 2024 to a low of 85.61% in Q4 2023.
- A 4-year average of 43.11% and a median of 42.27% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 7058 bps in 2024 and sank 4264 bps in 2025, its largest moves.
- Lexeo Therapeutics' Return on Capital Employed stood at 85.61% in 2023, then jumped by 82 bps to 15.03% in 2024, then slumped by 284 bps to 57.67% in 2025, then surged by 31 bps to 39.86% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 39.86%, 57.67%, and 19.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -39.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.86% |
| Dec 31, 2025 | -57.67% |
| Sep 30, 2025 | -19.92% |
| Jun 30, 2025 | -32.13% |
| Mar 31, 2025 | -29.56% |
| Dec 31, 2024 | -15.03% |
| Sep 30, 2024 | -59.80% |
| Jun 30, 2024 | -44.68% |
| Mar 31, 2024 | -46.82% |
| Dec 31, 2023 | -85.61% |